- Home
- NXTC vs BOXL Comparison
NXTC vs BOXL Comparison
Compare NXTC & BOXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- BOXL
- Stock Information
- Founded
- NXTC 2015
- BOXL 1985
- Country
- NXTC United States
- BOXL United States
- Employees
- NXTC N/A
- BOXL N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- BOXL Telecommunications Equipment
- Sector
- NXTC Health Care
- BOXL Telecommunications
- Exchange
- NXTC Nasdaq
- BOXL Nasdaq
- Market Cap
- NXTC 13.0M
- BOXL 10.9M
- IPO Year
- NXTC 2019
- BOXL 2017
- Fundamental
- Price
- NXTC $10.77
- BOXL $1.71
- Analyst Decision
- NXTC Strong Buy
- BOXL Buy
- Analyst Count
- NXTC 2
- BOXL 3
- Target Price
- NXTC $25.50
- BOXL $5.00
- AVG Volume (30 Days)
- NXTC 49.2K
- BOXL 11.6M
- Earning Date
- NXTC 11-06-2025
- BOXL 11-12-2025
- Dividend Yield
- NXTC N/A
- BOXL N/A
- EPS Growth
- NXTC N/A
- BOXL N/A
- EPS
- NXTC N/A
- BOXL N/A
- Revenue
- NXTC N/A
- BOXL $113,560,000.00
- Revenue This Year
- NXTC N/A
- BOXL N/A
- Revenue Next Year
- NXTC N/A
- BOXL N/A
- P/E Ratio
- NXTC N/A
- BOXL N/A
- Revenue Growth
- NXTC N/A
- BOXL N/A
- 52 Week Low
- NXTC $2.69
- BOXL $1.06
- 52 Week High
- NXTC $19.20
- BOXL $10.65
- Technical
- Relative Strength Index (RSI)
- NXTC 77.64
- BOXL 42.12
- Support Level
- NXTC $6.23
- BOXL $1.90
- Resistance Level
- NXTC $13.17
- BOXL $2.16
- Average True Range (ATR)
- NXTC 0.91
- BOXL 0.17
- MACD
- NXTC 0.50
- BOXL -0.07
- Stochastic Oscillator
- NXTC 67.51
- BOXL 3.91
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About BOXL Boxlight Corporation
Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions including flat panels, LED video walls, and digital signage. The company also distributes science, technology, engineering, and math (or STEM) products, including 3D printing and robotics solutions and a portable science lab.